50 results about "Streptococcus suis" patented technology

The invention discloses application of epimedin A in preparation of a streptococcus suis type 2 capsule inhibitor, and belongs to the technical field of biological medicine. The compound can effectively inhibit the synthesis function of the streptococcus suis type 2 capsule, further enhances the removal effect of a host on the streptococcus suis type 2, reduces the pathogenicity of bacteria, and provides a new candidate compound and idea for preparing a capsule inhibitor of the streptococcus suis type 2 and researching and developing a novel medicine for treating streptococcus suis type 2 infection.

The invention belongs to the technical field of biology, and particularly relates to a quintuple fluorescent PCR detection reagent for porcine respiratory pathogens and application of the quintuple fluorescent PCR detection reagent. The quintuple fluorescent PCR detection reagent disclosed by the invention can achieve the purpose of simultaneously identifying and detecting actinobacillus pleuropneumoniae, haemophilus parasuis, mycoplasma hyopneumoniae, pasteurella multocida and / or streptococcus suis, and has the advantages of simplicity, convenience and rapidness in operation, high accuracy, high sensitivity and good repeatability; the method has important significance on rapid and accurate detection and epidemic disease prevention and control of clinical porcine respiratory pathogens.

This invention discloses an antimicrobial peptide cAMP-1 derived from the intestinal microorganisms of wild rodents and its applications, belonging to the field of biotechnology. The amino acid sequence of the antimicrobial peptide cAMP-1 is shown in SEQ ID NO:1. The antimicrobial peptide cAMP-1 exhibits highly efficient, rapid, and safe antimicrobial activity against Streptococcus suis type II. It significantly inhibits bacterial growth even at low concentrations, with a minimum inhibitory concentration (MIC) of 16 µg / mL. Time-kinetic kinetics results show that the antimicrobial peptide can kill all Streptococcus suis type II within 30 min and 15 min at concentrations of 2×MIC and 4×MIC, respectively. Furthermore, within several times the effective concentration range, the peptide exhibits almost no hemolytic activity and low cytotoxicity within a safe dosage range, demonstrating its promising application as a novel anti-infective candidate drug.

The application relates to a protective antigen of streptococcus suis disease and application thereof, and belongs to the technical field of biological vaccines. The amino acid sequence shown in SEQ ID No. 1 provided in the application is used as a protective antigen of streptococcus suis disease. The protective antigen is obtained by codon optimization of the nucleotide sequence shown in SEQ ID No. 2, construction of an expression vector and prokaryotic expression, and the protective antigen is verified to be capable of providing good immune cross-protection for type 2 and type 7 streptococcus suis infection in different ways. The application scheme has important significance for research on a general vaccine candidate antigen of multiple serotypes of streptococcus suis and scientific prevention and control of the disease.

The invention belongs to the technical field of biology, and discloses a polypeptide with broad-spectrum antibacterial activity and a preparation method and application thereof. The antibacterial peptide or the salt thereof is disclosed for the first time, the antibacterial peptide has a good antibacterial effect on common pathogenic bacteria (such as staphylococcus aureus, escherichia coli, salmonella enteritidis and streptococcus suis) and oral pathogenic bacteria (such as fusobacterium nucleatum and porphyromonas gingivalis), and the antibacterial peptide shows slight cytotoxicity on mammalian cells only under high concentration; and the safety is relatively high.

The invention discloses application of elaifolin in preparation of a medicine for resisting streptococcus suis, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the elaifolin can efficiently inhibit and kill a plurality of serotype streptococcus suis and obviously inhibit or remove biological membranes of the streptococcus suis. The elaifolin can be applied to preparation of anti-streptococcus suis bacteriostasis and sterilization medicines, medicines for treating streptococcus suis infection and medicines for inhibiting or removing streptococcus suis biological membranes. According to the application disclosed by the invention, new medicinal value of the elaifolin is found, and a new prevention and treatment strategy is provided for streptococcus suis drug resistance and biofilm infection; the elaifolin can efficiently act on the multi-drug-resistant streptococcus suis, and a new direction is provided for relieving antibiotic drug resistance crisis.

The invention relates to the technical field of veterinary vaccines, in particular to streptococcus suis capsular polysaccharide as well as a preparation method and application thereof. The preparation method of the streptococcus suis capsular polysaccharide is high in specificity, convenient to operate, good in repeatability, high in yield and low in cost, the extraction cost of the streptococcus suis capsular polysaccharide is further reduced, and meanwhile the polysaccharide yield is effectively increased. When the streptococcus suis capsular polysaccharide prepared by the method is further used for preparing a streptococcus suis capsular polysaccharide vaccine, the prepared streptococcus suis capsular polysaccharide vaccine shows more slight clinical symptoms than a streptococcus suis whole-cell inactivated vaccine, and has better biological safety and an excellent challenge protection effect.

The application belongs to the field of microorganisms and particularly relates to a Streptococcus suis type 2 high-yield capsular polysaccharide strain and application. From 46 Streptococcus suis type 2 strains clinically isolated and identified by the applicant, a capsular polysaccharide high-yield strain is screened out, and the preservation number of the strain is CCTCC NO: M20242085. The applicant further explores and optimizes the process of the Streptococcus suis type 2 high-yield capsular polysaccharide, so that the original fermentation process, which pays attention to the purpose of bacterial growth and reproduction, is changed to be more conducive to the production of high-quality capsular polysaccharide, and the yield of the capsular polysaccharide is further improved. The method has good controllability and repeatability and is conducive to large-scale process production. The application has important significance for the commercial production of the Streptococcus suis type 2 high-yield capsular polysaccharide.

The invention relates to a multiplex fluorescent quantitative PCR (polymerase chain reaction) detection method for streptococcus equi subsp. Zooepidemicus virulent strains causing swine streptococcosis, and belongs to the technical field of bacterial detection. The invention provides a primer probe group which can be used for simultaneously detecting M protein variable region genes (szm-variant) of streptococcus equi subsp.zooepidemicus, conserved genes (comB) in subsp.zooepidemicus and central nervous system infection related virulence genes (bifA) of streptococcus equi subsp.zooepidemicus through Taqman probe triple fluorescent quantitative PCR (Polymerase Chain Reaction), and is shown as SEQ ID NO.1-9 in a sequence table. The multiplex fluorescent quantitative PCR detection method for the streptococcus equi subsp. Zooepidemicus virulent strain causing the swine streptococcosis can complete nucleic acid amplification and result judgment within 1 hour. According to the detection method, the amplification result is judged through the threshold cycle number (Ct value), electrophoresis detection is not needed, and the problems of pollution, false positive and the like of an amplification product can be avoided. The detection method provided by the invention has the characteristics of simplicity, convenience and rapidness in operation, high specificity, high sensitivity and good stability.

The invention discloses a chicken intestinal bacteriophage source antibacterial peptide, and belongs to the technical field of biology. The antibacterial peptide (CGV-AMP-1) disclosed by the invention shows excellent effects of high efficiency, rapidness and safety on staphylococcus capitis and streptococcus suis type II; the antibacterial peptide (CGV-AMP-1) can inhibit the growth of bacteria at extremely low concentration (MIC 8 g / ml), and has strong bactericidal ability (MBC 32 g / ml); the time sterilization dynamics experiment proves that the bacteria can be completely killed within 120 minutes; meanwhile, the peptide is extremely high in safety, almost has no hemolytic activity in a range of several times of effective concentration, is extremely low in cytotoxicity, and shows huge potential as a novel anti-infection drug.

The invention is applicable to the technical field of bioengineering, and provides a streptococcus suis bacteriophage antibacterial protein Lys8387 as well as a preparation method and application thereof, and the amino acid sequence of the streptococcus suis bacteriophage antibacterial protein Lys8387 is shown as SEQ ID NO.2. A novel bacteriophage antibacterial protein capable of playing splitting and depolymerizing double activities on streptococcus suis is constructed through a genetic engineering technology, and the lyase is novel in sequence, shows strong bactericidal activity on multi-drug-resistant streptococcus suis, can be independently used or compounded with other substances for use, or can be prepared into an enzyme preparation, and can be used for preparing an antibacterial agent for multiple drug-resistant streptococcus suis. The compound not only has bactericidal activity on streptococcus suis, but also has a degradation effect on capsular polysaccharide of streptococcus suis, K2 type klebsiella pneumoniae and the like, and a thought is provided for preparing a medicine for preventing and treating diseases caused by infection of microorganisms such as streptococcus suis and the like.

The present application relates to the animal medical technology field, especially to the Streptococcus suis strain and the vaccine thereof for prevention and treatment, and provides Streptococcus suis type 2, type 3 and type 9 strains screened and obtained, and a trivalent inactivated vaccine prepared by mixing the three strains, which can safely and effectively prevent and protect against the attack of the three pathogenic bacteria of Streptococcus suis.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide with activity of inhibiting human pathogenic bacteria as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common genital tract bacteria (such as staphylococcus aureus, gardnerella and candida albicans), oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

The invention provides a streptococcus suis serotype 2 virulent strain resistant to multiple antibiotics and application, and belongs to the technical field of vaccine preparation, the streptococcus suis serotype 2 resistant to multiple antibiotics is preserved in China Center for Type Culture Collection on December 6, 2024, the preservation number is CCTCC NO: M20242747, the classification name is streptococcus suis serotype 2 S068, the prepared streptococcus suis serotype 2 polysaccharide conjugate vaccine is applied, and the streptococcus suis serotype 2 polysaccharide conjugate vaccine can be used for preparing the streptococcus suis serotype 2 polysaccharide conjugate vaccine. The protection rate is higher, and good adaptability, high efficiency and safety in a complex clinical environment are shown.

The invention belongs to the technical field of microbiological detection, and particularly relates to a primer and a method for detecting a streptococcus suis drug-resistant gene and application of the primer, nucleotide sequences of the primer are shown as SEQ ID NO.1-SEQ ID NO.2. The detection primer has specificity, and accuracy and reliability of the detection primer can be ensured.

The invention is applicable to the technical field of biology, and provides a streptococcus suis type 2 multi-epitope inhalation type subunit vaccine and application thereof. According to the invention, 4 CTL epitopes, 7 HTL epitopes and 6 B cell epitopes are screened out aiming at conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, the epitopes are fused by AAY / GPGPG / EAAAK linkers, L7 / L12 ribosomal protein is introduced as an adjuvant, and the inhalation type subunit vaccine 1022-SpaA V3 is constructed; the vaccine can improve the levels of sIgA and serum IgG of respiratory mucosa and activate related immune cells by virtue of 60 micrograms of intranasal primary immunization-enhanced immunization, so that a mucosa and system dual immune mechanism is formed; the survival rate of mice after SS2 multi-strain challenge reaches up to 100%, and the bacterial load can be reduced; and the vaccine is safe and non-toxic, is inhaled, saves cost and is suitable for industrial large-scale production.

The invention pertains to a stable vaccine formulation comprising a protein denoted as IdeSsuis and the vaccine formulation comprising reduced cysteine. The invention also pertains to a vaccine formulation comprising a protein denoted as IdeSsuis and the vaccine formulation comprising reduced cysteine for use in a method for protecting pigs against a pathogenic infection of S. suis bacteria. The invention also pertains to methods of preparing the vaccine formulation, preferably wherein the method comprises a step of lyophilizing the vaccine formulation.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide for regulating and controlling micro-ecology as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni), genital tract pathogenic bacteria (such as staphylococcus aureus, gardnebacterium and enterococcus faecalis) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.

This invention discloses an engineered strain of Streptococcus suis Δ07335-hSLY (classification name: Streptococcus suis Δ07335-hSLY, deposit date: May 13, 2026, deposit number: CCTCC NO: M2026937), its construction method, and applications, relating to the fields of microbial genetic engineering and drug screening technology. This invention uses Streptococcus suis SC19 strain as the starting strain and obtains the engineered strain SC19Δ07335 by knocking out the 07335 gene in its genome using homologous recombination technology. Compared with the starting strain SC19, the expression level of the hemolysin SLY gene in this engineered strain is significantly upregulated, increasing the success rate of the hemolysis test in the culture supernatant from 30% to 100%. Simultaneously, the expression of the capsular polysaccharide synthesis gene CPS is downregulated, the capsule becomes thinner, and the in vivo virulence is significantly reduced. The anti-hemolytic active compound screening system established based on this engineered strain is stable and reliable, and compounds with anti-SLY activity, such as baicalin, have been successfully screened. Animal experiments have verified that the survival rate of mice in the medium and high dose treatment groups of baicalin reached 100%.

The application provides a kit for detecting penicillin and amoxicillin resistance of streptococcus suis and application thereof, and belongs to the technical field of molecular biology detection. The kit comprises a primer pair and AlwNI restriction endonuclease; the primer pair comprises primers PBP1a-2083F and PBP1a-2083R, and the sequences are shown in SEQ ID NO:1 and SEQ ID NO:2 respectively. The kit is used for detecting penicillin and amoxicillin resistance of streptococcus suis, has the advantages of high specificity, high sensitivity, low detection cost and low technical requirement, and provides reliable technology for monitoring penicillin and amoxicillin resistance of streptococcus suis in clinic.

The present application relates to the technical field of fermentation medium, more specifically, it relates to a high-density fermentation medium for streptococcus suis and preparation and application thereof.The medium comprises beef infusion powder 1-5 parts, tryptone 1-10 parts, pancreatic casein peptone 1-10 parts, soybean peptone 1-5 parts, dipotassium hydrogen phosphate 1-5 parts, sodium chloride 1-10 parts, yeast extract 1-10 parts and glucose 1-5 parts.

The application discloses a bacteriocin expressed by bacillus subtilis WB800N and application thereof. The original sequence of the bacteriocin is a bacteriocin PA from bacillus polymyxa, the nucleotide sequence of the bacteriocin PA is shown as SEQ ID NO:1, and the amino acid sequence is shown as SEQ ID NO:2. The bacteriocin PA coding gene is modified by a tag and optimized by a codon to obtain a bacteriocin PFH, the nucleotide sequence of the bacteriocin PFH is shown as SEQ ID NO:3, and the amino acid sequence is shown as SEQ ID NO:4. The bacteriocin PFH expressed by the bacillus subtilis WB800N has a good bacteriostatic effect on gram-positive bacteria such as streptococcus suis, enterococcus faecium, staphylococcus aureus and bacillus subtilis, and has a wide application prospect in the development of a new type of replacement product for infection treatment and a feed antibacterial peptide.

The application belongs to the technical field of biological medicine, and specifically discloses a kind of hybrid peptide B5PL and its application in preparation of anti-infection drugs.The amino acid sequence of the hybrid peptide B5PL is shown as SEQ ID NO.1, and research proves that the hybrid peptide B5PL can destroy bacterial cell membranes, regulate immune homeostasis, and thus play a role in preventing and treating drug-resistant Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, Streptococcus suis and Actinobacillus pleuropneumoniae infections.In a mouse peritoneal infection MRSA model, B5PL can significantly reduce lung pathological damage caused by infection, specifically manifested as improved alveolar structure integrity, reduced inflammatory cell infiltration, and significantly improved mouse survival rate, showing good anti-infection treatment potential.The hybrid peptide B5PL provided by the application is expected to become an antibiotic replacement drug, and has good application prospect.

The invention relates to the technical field of biology, and particularly discloses streptococcus suis lyase Ply2413 and application thereof. Wherein the amino acid sequence of the lyase is as shown in SEQ ID NO: 1, or the lyase is a functional variant which has the same CHAP catalytic structural domain and SH3b binding structural domain as the lyase and retains broad-spectrum splitting activity. The lyase can be prepared from the coding gene of the lyase through a recombinant expression system. The preparation method comprises the following steps: cloning a gene for coding the lyase, constructing a recombinant expression vector, transforming host cells, carrying out induced expression, purifying to obtain target lyase, and further preparing various antibacterial products. The streptococcus suis lyase Ply2413 disclosed by the invention can be used for preventing and controlling streptococcus suis, staphylococcus aureus and streptococcus uberis infection, and has the advantages of wide lysis spectrum, multiple action targets and good environmental stability; in addition, the preparation method disclosed by the invention has the advantages of simplicity and convenience in operation, high expression efficiency, large-scale production and high technical repeatability.

The invention relates to the technical field of streptococcus suis drug resistance gene detection, and particularly discloses a streptococcus suis drug resistance gene sextuple PCR detection kit and application thereof. The core of the kit is a specific primer combination, the nucleotide sequences of the specific primer combination are as shown in SEQ ID NO: 1-12, and the specific primer combination respectively aims at six key drug-resistant genes of streptococcus suis: ermB, tet (O), patB, aac (6 '')-Ie-ah (2 ')-Ia, optrA and lsa (E). By optimizing the primer concentration and reaction conditions, an efficient and stable sextuple PCR detection system is established, and amplification and detection of the six genes can be synchronously completed in a single reaction. The method has the advantages of high specificity, high sensitivity, good repeatability, simplicity and convenience in operation and the like. A high-throughput and low-cost molecular detection tool is provided for rapid diagnosis, medication guidance and epidemiological monitoring of streptococcus suis clinical multiple drug resistance, and the application prospect is wide.

This invention belongs to the field of vaccine preparation technology, and discloses the application of Streptococcus suis type 2 membrane vesicles in the preparation of vaccines and / or immune enhancers. This invention is the first to use Streptococcus suis type 2 membrane vesicles as a vaccine for animal immunization. Animal experiments have demonstrated that the Streptococcus suis type 2 membrane vesicles of this invention can induce high levels of antibodies and have a significant effect in preventing Streptococcus suis type 2 infection. It can be developed and applied as a novel vaccine to prevent Streptococcus suis type 2 disease and avoid bacterial resistance, demonstrating good practical application value. Simultaneously, this invention also discloses a vaccine for preventing Streptococcus suis type 2 and an immune enhancer.

The invention provides lactobacillus plantarum NX87 and application thereof, the lactobacillus plantarum NX87 is lactobacillus plantarum NX87, the lactobacillus plantarum NX87 is preserved in the Guangdong Microbial Culture Collection Center on April 23, 2025, the address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No. 66203; the lactobacillus plantarum NX87 is used for preventing and treating the streptococcus suis, the escherichia coli and the balloon mycosis, and the lactobacillus plantarum NX87 is used for preventing and treating the streptococcus suis, the escherichia coli and the balloon mycosis. The strain disclosed by the invention has relatively strong inhibition capability on streptococcus suis, escherichia coli and balloon mycosis, has relatively strong tolerance to acid, has good cholate tolerance, and is beneficial to colonization at parts such as intestinal mucosa and the like.

This invention discloses a novel antimicrobial peptide CGV-AMP-4 derived from chicken intestinal bacteriophage and its applications, belonging to the field of biotechnology. The antimicrobial peptide CGV-AMP-4 of this invention exhibits broad-spectrum antimicrobial activity, with particularly significant effects against Streptococcus suis type II. Simultaneously, this peptide demonstrates extremely high safety, exhibiting almost no hemolytic activity within several times the effective concentration range and very low cytotoxicity, showcasing great potential as a novel anti-infective drug.